Finland· FI-REL-REL41495
Provenge
A sipuleucel-t product containing autologous blood mononuclear cells activated with pap-gm-csf, registered in Finland by Dendron UK Ltd. The same ATC class is registered in 2 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Sipuleucel-t is registered in 2 of 19 countries.
Countries holding a registration under ATC L03AX17 (sipuleucel-t), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 2 of them publish a price we can compare per daily dose
Sipuleucel-t · ATC L03AX17
2 / 19 countries
- Finlandprice
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Autologous blood mononuclear cells activated with PAP-GM-CSF
- Manufacturer
- Dendron UK Ltd
- Country
- Finland (FI)
- ATC code
- L03AX17
- ATC class
- Sipuleucel-T
- Defined daily dose
- 0.071 DE, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
288 interactions on record for sipuleucel-t.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sipuleucel-t · interactions on record
288 records
- 2 severe
- 286 moderate
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L03AX17
Sipuleucel-t, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/152d1843-baa2-484c-a42b-180ae040d0e7 GET /v1/drugs/152d1843-baa2-484c-a42b-180ae040d0e7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusioneste, dispersio",
"route": null,
"ddd_unit": null,
"strength": "50 x10 000 000 CD54+-solua/250 ml",
"atc_label": "sipuleucel-T",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/13/867/001",
"fimea_rel_id": "REL41495",
"authorised_at": "2013-09-06"
}See everything about sipuleucel-t.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.